Movement Alert｜Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum

Market Focus00:14

On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its ARO-MAPT program targeting Alzheimer's disease.

On the news front, the company's ARO-MAPT drug, developed on its proprietary TRiM BBB platform, utilizes siRNA conjugated to a transferrin receptor-targeting ligand delivered via subcutaneous injection to cross the blood-brain barrier and silence the MAPT gene across the entire brain for treatment of Alzheimer's disease and other tauopathies. Preclinical data demonstrated that ARO-MAPT achieved 70-80% mRNA knockdown in non-human primates, covering multiple cell types including neurons and astrocytes. This represents a significant validation of the company's blood-brain barrier delivery technology platform for CNS RNAi therapeutics.

Within the Biotechnology sector, individual stocks showed mixed performance. Among notable movers, uniQure NV up 76.77%, AbbVie down 0.13%, Gilead Sciences down 0.28%, Amgen down 0.18%, Nuvalent Inc. flat 0%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186223274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186223274","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum","media":"Market Focus","content":"<p><p>On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its ARO-MAPT program targeting Alzheimer's disease.</p><p>On the news front, the company's ARO-MAPT drug, developed on its proprietary TRiM BBB platform, utilizes siRNA conjugated to a transferrin receptor-targeting ligand delivered via subcutaneous injection to cross the blood-brain barrier and silence the MAPT gene across the entire brain for treatment of Alzheimer's disease and other tauopathies. Preclinical data demonstrated that ARO-MAPT achieved 70-80% mRNA knockdown in non-human primates, covering multiple cell types including neurons and astrocytes. This represents a significant validation of the company's blood-brain barrier delivery technology platform for CNS RNAi therapeutics.</p><p>Within the Biotechnology sector, individual stocks showed mixed performance. Among notable movers, uniQure NV up 76.77%, AbbVie down 0.13%, Gilead Sciences down 0.28%, Amgen down 0.18%, Nuvalent Inc. flat 0%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its ARO-MAPT program targeting Alzheimer's disease.</p><p>On the news front, the company's ARO-MAPT drug, developed on its proprietary TRiM BBB platform, utilizes siRNA conjugated to a transferrin receptor-targeting ligand delivered via subcutaneous injection to cross the blood-brain barrier and silence the MAPT gene across the entire brain for treatment of Alzheimer's disease and other tauopathies. Preclinical data demonstrated that ARO-MAPT achieved 70-80% mRNA knockdown in non-human primates, covering multiple cell types including neurons and astrocytes. This represents a significant validation of the company's blood-brain barrier delivery technology platform for CNS RNAi therapeutics.</p><p>Within the Biotechnology sector, individual stocks showed mixed performance. Among notable movers, uniQure NV up 76.77%, AbbVie down 0.13%, Gilead Sciences down 0.28%, Amgen down 0.18%, Nuvalent Inc. flat 0%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1186223274","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186223274","pubTimestamp":1781712870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"动静快讯|Arrowhead Research Corporation常规交易涨5.06%，阿尔茨海默病siRNA药物临床进展继续推动势头","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"On June 17, Arrowhead Research Corporation rose 5.06% in regular trading, trading at $80.425/share, with turnover of $51.87 million. The stock continues to be catalyzed by clinical progress of its ARO-MAPT program targeting Alzheimer's disease.On the news front, the company's ARO-MAPT drug, developed on its proprietary TRiM BBB platform, utilizes siRNA conjugated to a transferrin receptor-targeting ligand delivered via subcutaneous injection to cross the blood-brain barrier and silence the MAPT gene across the entire brain for treatment of Alzheimer's disease and other tauopathies. Preclinical data demonstrated that ARO-MAPT achieved 70-80% mRNA knockdown in non-human primates, covering multiple cell types including neurons and astrocytes. This represents a significant validation of the company's blood-brain barrier delivery technology platform for CNS RNAi therapeutics.Within the Biotechnology sector, individual stocks showed mixed performance. Among notable movers, uniQure NV up 76.77%, AbbVie down 0.13%, Gilead Sciences down 0.28%, Amgen down 0.18%, Nuvalent Inc. flat 0%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186223274","isCrawlerRequest":true}